Investment Summary

In August 2018 Ikarovek was formed to commercialise certain orphan assets from Quethera, a spin-out from the University of Cambridge, which was acquired by Astellas Pharma Inc.

Initially Ikarovek is working on early stage assets intended for the treatment of diabetic macular edama.